JP2023511595A5 - - Google Patents
Info
- Publication number
- JP2023511595A5 JP2023511595A5 JP2022545057A JP2022545057A JP2023511595A5 JP 2023511595 A5 JP2023511595 A5 JP 2023511595A5 JP 2022545057 A JP2022545057 A JP 2022545057A JP 2022545057 A JP2022545057 A JP 2022545057A JP 2023511595 A5 JP2023511595 A5 JP 2023511595A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- amino acid
- seq
- acid sequence
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026038528A JP2026116924A (ja) | 2020-01-27 | 2026-03-11 | 抗tigitアンタゴニスト抗体を用いたがんを処置するための方法 |
Applications Claiming Priority (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966448P | 2020-01-27 | 2020-01-27 | |
| US62/966,448 | 2020-01-27 | ||
| US202062985822P | 2020-03-05 | 2020-03-05 | |
| US62/985,822 | 2020-03-05 | ||
| US202062994272P | 2020-03-24 | 2020-03-24 | |
| PCT/US2020/024526 WO2021194481A1 (en) | 2020-03-24 | 2020-03-24 | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| USPCT/US2020/024526 | 2020-03-24 | ||
| US62/994,272 | 2020-03-24 | ||
| US202063059054P | 2020-07-30 | 2020-07-30 | |
| US63/059,054 | 2020-07-30 | ||
| US202063059960P | 2020-07-31 | 2020-07-31 | |
| US63/059,960 | 2020-07-31 | ||
| US202063074827P | 2020-09-04 | 2020-09-04 | |
| US202063074807P | 2020-09-04 | 2020-09-04 | |
| US63/074,807 | 2020-09-04 | ||
| PCT/US2020/049415 WO2022050954A1 (en) | 2020-09-04 | 2020-09-04 | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| US63/074,827 | 2020-09-04 | ||
| USPCT/US2020/049415 | 2020-09-04 | ||
| US202063085890P | 2020-09-30 | 2020-09-30 | |
| US63/085,890 | 2020-09-30 | ||
| US202063105198P | 2020-10-23 | 2020-10-23 | |
| US63/105,198 | 2020-10-23 | ||
| US202063114517P | 2020-11-16 | 2020-11-16 | |
| US63/114,517 | 2020-11-16 | ||
| US202063124693P | 2020-12-11 | 2020-12-11 | |
| US63/124,693 | 2020-12-11 | ||
| US202063127109P | 2020-12-17 | 2020-12-17 | |
| US63/127,109 | 2020-12-17 | ||
| PCT/US2021/015143 WO2021154761A1 (en) | 2020-01-27 | 2021-01-26 | Methods for treatment of cancer with an anti-tigit antagonist antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026038528A Division JP2026116924A (ja) | 2020-01-27 | 2026-03-11 | 抗tigitアンタゴニスト抗体を用いたがんを処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511595A JP2023511595A (ja) | 2023-03-20 |
| JP2023511595A5 true JP2023511595A5 (cg-RX-API-DMAC7.html) | 2024-02-05 |
Family
ID=74626264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545057A Pending JP2023511595A (ja) | 2020-01-27 | 2021-01-26 | 抗tigitアンタゴニスト抗体を用いたがんを処置するための方法 |
| JP2026038528A Pending JP2026116924A (ja) | 2020-01-27 | 2026-03-11 | 抗tigitアンタゴニスト抗体を用いたがんを処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026038528A Pending JP2026116924A (ja) | 2020-01-27 | 2026-03-11 | 抗tigitアンタゴニスト抗体を用いたがんを処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4096646A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023511595A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220133243A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115315256A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021212662A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165187A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294800A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009170A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202142230A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021154761A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3175127A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2021257503A1 (en) * | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
| KR20240028452A (ko) * | 2021-07-02 | 2024-03-05 | 제넨테크, 인크. | 암을 치료하기 위한 방법 및 조성물 |
| CN118871463A (zh) * | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| JP2024532744A (ja) * | 2021-08-10 | 2024-09-10 | メルク・シャープ・アンド・ドーム・エルエルシー | T1gitアンタゴニスト、pd-1アンタゴニスト、及び(1又は複数の)化学療法剤を含む治療的組合せ |
| US20250064794A1 (en) * | 2021-08-10 | 2025-02-27 | Eisai R&D Management Co., Ltd. | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
| WO2023040804A1 (zh) * | 2021-09-14 | 2023-03-23 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和化疗药的药物组合及其使用方法 |
| JP2024535793A (ja) * | 2021-09-15 | 2024-10-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Pd-1に特異的に結合するタンパク質及びその医薬的使用 |
| MX2024007749A (es) * | 2021-12-22 | 2024-07-01 | Genentech Inc | Formulaciones clinicas de anticuerpos anti-tigit. |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| WO2024130026A1 (en) * | 2022-12-16 | 2024-06-20 | Elevar Therapeutics, Inc. | Methods and compositions for treatment of subjects with hepatic impairments |
| KR20250118852A (ko) * | 2022-12-23 | 2025-08-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| CN121241067A (zh) * | 2023-03-31 | 2025-12-30 | 基因泰克公司 | 用抗tigit抗体治疗肿瘤的方法 |
| CN116716393A (zh) * | 2023-05-10 | 2023-09-08 | 首都医科大学附属北京儿童医院 | 用于检测caebv和im宿主差异甲基化基因的物质、试剂盒及其应用 |
| WO2024263195A1 (en) * | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| TW202515614A (zh) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | 治療非小細胞肺癌之方法及組成物 |
| WO2025174933A1 (en) * | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
| CN121003695A (zh) * | 2024-05-24 | 2025-11-25 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |
| CN118919054B (zh) * | 2024-07-12 | 2025-09-30 | 中国医学科学院肿瘤医院 | 基于聚类方法的特定疾病的复发概率的预测方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| KR100441557B1 (ko) | 1994-07-21 | 2005-08-05 | 아크조 노벨 엔.브이. | 고리형케톤과산화물조성물 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| AU2005250484B2 (en) | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
| WO2014046730A1 (en) | 2012-09-24 | 2014-03-27 | Ventana Medical Systems, Inc. | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| DK3294770T4 (da) | 2015-05-12 | 2024-05-21 | Hoffmann La Roche | Terapeutiske og diagnostiske fremgangsmåder til cancer |
| EP3303632B2 (en) | 2015-05-29 | 2023-05-10 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US20200399376A1 (en) * | 2018-02-26 | 2020-12-24 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
-
2021
- 2021-01-26 IL IL294800A patent/IL294800A/en unknown
- 2021-01-26 TW TW110102913A patent/TW202142230A/zh unknown
- 2021-01-26 CN CN202180022830.2A patent/CN115315256A/zh active Pending
- 2021-01-26 AU AU2021212662A patent/AU2021212662A1/en active Pending
- 2021-01-26 JP JP2022545057A patent/JP2023511595A/ja active Pending
- 2021-01-26 MX MX2022009170A patent/MX2022009170A/es unknown
- 2021-01-26 EP EP21705841.1A patent/EP4096646A1/en active Pending
- 2021-01-26 WO PCT/US2021/015143 patent/WO2021154761A1/en not_active Ceased
- 2021-01-26 CA CA3165187A patent/CA3165187A1/en active Pending
- 2021-01-26 KR KR1020227029306A patent/KR20220133243A/ko active Pending
-
2026
- 2026-03-11 JP JP2026038528A patent/JP2026116924A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514969A5 (cg-RX-API-DMAC7.html) | ||
| CN113230398B (zh) | 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体 | |
| JP2020508317A5 (cg-RX-API-DMAC7.html) | ||
| US20190160148A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| US20250295765A1 (en) | Drug combination for treating non-small cell lung cancer | |
| WO2025002280A1 (en) | Combination therapies for the treatment of cancer | |
| JP2023531200A5 (cg-RX-API-DMAC7.html) | ||
| US20230338521A1 (en) | Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor | |
| EP4144371A1 (en) | Combination drug for treating kidney cancer | |
| US20240343807A1 (en) | Pharmaceutical composition for treating small cell lung cancer | |
| EP4736872A1 (en) | Treatment method and use of pharmaceutical combination containing conjugate | |
| EP4735037A1 (en) | Combination therapies for the treatment of non-small cell lung cancer | |
| CN121443321A (zh) | 治疗组合及其用途和治疗方法 | |
| CN120752053A (zh) | 含抗tim-3抗体的药物组合 | |
| CN119894516A (zh) | 用于治疗晚期实体瘤的组合物和方法 | |
| JP2024502465A5 (cg-RX-API-DMAC7.html) | ||
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| JP2022531894A5 (cg-RX-API-DMAC7.html) | ||
| US20210363253A1 (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer | |
| US20250099605A1 (en) | Treatment of non-small cell lung cancer using sacituzumab govitecan and an anti-pd-1 antibody or antigen binding fragment thereof | |
| US20240042020A1 (en) | Anti-garp-tgf-beta1/pd-1 combination therapy | |
| JP2024535034A5 (cg-RX-API-DMAC7.html) | ||
| WO2025072041A1 (en) | Use of an immunoconjugate for the treatment of non-small cell lung cancer | |
| CN118681010A (zh) | 用于治疗肺癌的药物组合 | |
| CN117642181A (zh) | 用于治疗食管癌的药物组合 |